Septerna, Inc.
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $26.70M | $-0.29 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | $26.50M | $-0.19 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | After market close | $24.10M | $-0.24 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $21.50M | $0.18 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | $212.00K | $-0.64 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 20, 2024 | After market close | – | – | – |
Press releases
Announcements Septerna filed with the SEC
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Septerna Announces Initiation of Phase 1 Clinical Trial of
Regulation FD disclosure · EX-99.1 to Form 8-K
Pioneering a New Era of GPCR Drug
Regulation FD disclosure · EX-99.2 to Form 8-K
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MRGPRX2 Negative Allosteric Modulator (NAM) for Mast Cell-Driven Diseases March 2, 2026 Nasdaq: SEPN *Data presented at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting © 2026 SEPTERNA
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Healthcare Conference 2026 January 2026 Nasdaq: SEPN
Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GPCR Drug Discovery September 2025 Corporate Presentation Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631,
Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
GPCR Drug Discovery March 2025 TD Cowen 45th Annual Health Care Conference Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance
Regulation FD disclosure · EX-99.1 to Form 8-K
Healthcare Conference 2025 January 2025 Nasdaq: SEPN
Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K